Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: Correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans

Journal of Inherited Metabolic Disease

Volumn 36, Issue 2, 2013, Pages 247-255

  De Ru, Minke H ^a   Van Der Tol, Linda ^a   Van Vlies, Naomi ^a   Bigger, Brian W ^b   Hollak, Carla E M ^a   Ijlst, Lodewijk ^a   Kulik, Wim ^a   Van Lenthe, Henk ^a   Saif, Muhammad A ^b   Wagemans, Tom ^a   Van Der Wal, Willem M ^c   Wanders, Ronald J ^a   Wijburg, Frits A ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATAN SULFATE; DISACCHARIDE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN COFACTOR; HEPARIN LYASE; IMMUNOGLOBULIN G ANTIBODY; LARONIDASE; N ACETYLGALACTOSAMINE 4 SULFATASE; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EFFECT SIZE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HURLER SYNDROME; LONG TERM CARE; MALE; MASS SPECTROMETRY; PHENOTYPE; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; STEADY STATE; URINALYSIS; URINARY EXCRETION; AGED; BLOOD; INFANT; METABOLISM; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS I; NEWBORN; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DERMATAN SULFATE; DISACCHARIDES; ENZYME REPLACEMENT THERAPY; FEMALE; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS I; YOUNG ADULT;

EID: 84879694169     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9538-2     Document Type: Article

References (24)

1. Brooks DA, Kakavanos R, Hopwood JJ (2003) Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 9:450-453
2. Church H, Tylee K, Cooper A et al (2007) Biochemical monitoring after haemopoietic stem cell transplant for Hurler syndrome (MPSIH): implications for functional outcome after transplant in metabolic disease. Bone Marrow Transplant 39:207-210
3. Clarke LA, Hemmelgarn H, Colobong K et al (2011) Longitudinal observations of serum heparin cofactor II-thrombin complex in treated Mucopolysaccharidosis I and II patients. J Inherit Metab Dis
4. Clarke LA, Wraith JE, Beck M et al (2009) Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123:229-240
5. de Jong JG, Wevers RA, Laarakkers C, Poorthuis BJ (1989) Dimethylmethylene blue-based spectrophotometry of glycosaminoglycans in untreated urine: a rapid screening procedure for mucopolysaccharidoses. Clin Chem 35:1472-1477
6. de Ru MH, Boelens JJ, Das AM et al (2011) Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis 6:55
7. Giugliani R, Rojas VM, Martins AM et al (2009) A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab 96:13-19
8. Kakkis ED, Muenzer J, Tiller GE et al (2001) Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182-188
9. Langford-Smith K, Arasaradnam M, Wraith JE, Wynn R, Bigger BW (2010) Evaluation of heparin cofactor II-thrombin complex as a biomarker on blood spots from mucopolysaccharidosis I, IIIA and IIIB mice. Mol Genet Metab 99:269-274
10. Langford-Smith KJ, Mercer J, Petty J et al (2011) Heparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J Inherit Metab Dis 34:499-508
11. Lawrence R, Lu H, Rosenberg RD, Esko JD, Zhang L (2008) Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods 5:291-292
12. Muenzer J, Wraith JE, Clarke LA (2009) Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123:19-29
13. Oguma T, Tomatsu S, Montano AM, Okazaki O (2007) Analytical method for the determination of disaccharides derived from keratan, heparan, and dermatan sulfates in human serum and plasma by high-performance liquid chromatography/turbo ionspray ionization tandem mass spectrometry. Anal Biochem 368:79-86
14. Pastores GM, Arn P, Beck M et al (2007) The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab 91:37-47
15. Pojasek K, Shriver Z, Kiley P, Venkataraman G, Sasisekharan R (2001) Recombinant expression, purification, and kinetic characterization of chondroitinase AC and chondroitinase B from Flavobacterium heparinum. Biochem Biophys Res Commun 286:343-351
16. Randall DR, Colobong KE, Hemmelgarn H et al (2008) Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol Genet Metab 94:456-461
17. Randall DR, Sinclair GB, Colobong KE, Hetty E, Clarke LA (2006) Heparin cofactor II-thrombin complex in MPS I: a biomarker of MPS disease. Mol Genet Metab 88:235-243
18. Saif MA, Bigger BW, Brookes KE et al (2012) Hematopoietic stem cell transplantation ameliorates the high incidence of neutralizing allo-antibodies observed in MPSI-Hurler after pharmacological enzyme replacement therapy. Haematologica
19. Sifuentes M, Doroshow R, Hoft R et al (2007) A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab 90:171-180
20. Tomatsu S, Montano AM, Oguma T et al (2010a) Dermatan sulfate and heparan sulfate as a biomarker for mucopolysaccharidosis I. J Inherit Metab Dis 33:141-150
21. Tomatsu S, Montano AM, Oguma T et al (2010b) Validation of disaccharide compositions derived from dermatan sulfate and heparan sulfate in mucopolysaccharidoses and mucolipidoses II and III by tandem mass spectrometry. Mol Genet Metab 99:124-131
22. Wraith JE, Beck M, Lane R et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 120:e37-e46
23. Wraith JE, Clarke LA, Beck M et al (2004) Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase). J Pediatr 144:581-588
24. Wynn RF, Wraith JE, Mercer J et al (2009) Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr 154:609-611